Brokerages Expect Alder BioPharmaceuticals (ALDR) Will Post Earnings of -$1.16 Per Share

Brokerages expect Alder BioPharmaceuticals (NASDAQ:ALDR) to announce ($1.16) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Alder BioPharmaceuticals’ earnings, with estimates ranging from ($1.37) to ($1.04). Alder BioPharmaceuticals posted earnings of ($1.48) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 21.6%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, August 14th.

On average, analysts expect that Alder BioPharmaceuticals will report full-year earnings of ($4.92) per share for the current fiscal year, with EPS estimates ranging from ($5.82) to ($4.05). For the next year, analysts expect that the firm will post earnings of ($3.73) per share, with EPS estimates ranging from ($5.46) to ($2.30). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Alder BioPharmaceuticals.

Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.50).

A number of analysts have recently weighed in on ALDR shares. Mizuho reaffirmed a “buy” rating and set a $29.00 price objective on shares of Alder BioPharmaceuticals in a research report on Wednesday, January 31st. Goldman Sachs Group started coverage on Alder BioPharmaceuticals in a research report on Tuesday, April 24th. They set a “neutral” rating and a $17.00 price objective on the stock. ValuEngine lowered Alder BioPharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Cowen set a $23.00 target price on Alder BioPharmaceuticals and gave the company a “buy” rating in a report on Monday, February 26th. Finally, BidaskClub raised Alder BioPharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, April 3rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the stock. Alder BioPharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $26.77.

Shares of Alder BioPharmaceuticals remained flat at $$15.55 during trading hours on Friday, MarketBeat.com reports. The stock had a trading volume of 437,558 shares, compared to its average volume of 914,253. Alder BioPharmaceuticals has a 1-year low of $8.60 and a 1-year high of $20.00. The company has a quick ratio of 13.30, a current ratio of 13.31 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -3.14 and a beta of 2.52.

In related news, insider Jeffrey T. L. Smith sold 12,161 shares of the stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $15.03, for a total value of $182,779.83. Following the transaction, the insider now owns 5,871 shares of the company’s stock, valued at $88,241.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 10.60% of the company’s stock.

A number of large investors have recently bought and sold shares of ALDR. Redmile Group LLC grew its holdings in shares of Alder BioPharmaceuticals by 0.4% during the fourth quarter. Redmile Group LLC now owns 6,505,766 shares of the biopharmaceutical company’s stock worth $74,491,000 after purchasing an additional 29,000 shares during the last quarter. Foresite Capital Management III LLC grew its holdings in shares of Alder BioPharmaceuticals by 3.3% during the first quarter. Foresite Capital Management III LLC now owns 2,942,130 shares of the biopharmaceutical company’s stock worth $37,365,000 after purchasing an additional 95,000 shares during the last quarter. Palo Alto Investors LP grew its holdings in shares of Alder BioPharmaceuticals by 0.5% during the first quarter. Palo Alto Investors LP now owns 1,849,832 shares of the biopharmaceutical company’s stock worth $23,493,000 after purchasing an additional 9,586 shares during the last quarter. Palo Alto Investors LLC grew its holdings in shares of Alder BioPharmaceuticals by 2,757.5% during the fourth quarter. Palo Alto Investors LLC now owns 1,840,246 shares of the biopharmaceutical company’s stock worth $21,071,000 after purchasing an additional 1,775,846 shares during the last quarter. Finally, Emerald Advisers Inc. PA grew its holdings in shares of Alder BioPharmaceuticals by 9.6% during the fourth quarter. Emerald Advisers Inc. PA now owns 1,730,028 shares of the biopharmaceutical company’s stock worth $19,809,000 after purchasing an additional 151,551 shares during the last quarter.

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.

Get a free copy of the Zacks research report on Alder BioPharmaceuticals (ALDR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit